Pirarubicin

TargetMol
Product Code: TAR-T6628
Supplier: TargetMol
CodeSizePrice
TAR-T6628-5mg5mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6628-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6628-10mg10mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6628-25mg25mg£157.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6628-50mg50mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6628-100mg100mg£345.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Pirarubicin is an anthracycline antibiotic. It is also a DNA/RNA synthesis inhibitor that intercalates into DNA and interacts with topoisomerase II, utilized as an antineoplastic agent.
CAS:
72496-41-4
Formula:
C32H37NO12
Molecular Weight:
627.643
Pathway:
Microbiology/Virology; Autophagy; DNA Damage/DNA Repair
Purity:
0.9866
SMILES:
COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
Target:
Topoisomerase; Antibacterial; Antibiotic; Autophagy

References

Cheng M Z, Yang B B, Zhan Z T, et al.MACC1 and Gasdermin-E (GSDME) regulate the resistance of colorectal cancer cells to irinotecan.Biochemical and Biophysical Research Communications.2023 Liu SY, et al. Chemotherapy, 2010, 56(2), 101-107. Li K, et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. Biochem Biophys Res Commun. 2015 May 1;460(2):380-5. Wang YD, et al. Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. J Asian Nat Prod Res. 2017 Oct 27:1-13. Okada M, et al. Br J Cancer, 1995, 71(3), 518-524. Nguyen HN, et al. Gynecol Oncol, 1992, 45(2), 164-173. Sugiyama T, et al. Jpn J Cancer Res, 1999, 90(7), 775-780. Hirano S, et al. J Pharm Pharmacol, 1991, 43(12), 848-854.